Varenicline treatment for smoking cessation in Asian populations: A pooled analysis of placebo-controlled trials conducted in six Asian countries

Current Medical Research and Opinion

Volumn 26, Issue 9, 2010, Pages 2165-2173

  Fagerström, Karl ^a   Nakamura, Masakazu ^b   Cho, Hong Jun ^c   Tsai, Shih Tzu ^d   Wang, Chen ^e   Davies, Simon ^f   Ma, Wendy ^f   Lee, Theodore C ^f   Russ, Cristina ^f  

^a Smokers Information Centre   (Sweden)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c University of Ulsan College of Medicine   (South Korea)

^d TZU CHI UNIVERSITY   (Taiwan)

^e CAPITAL MEDICAL UNIVERSITY   (China)

^f PFIZER INC   (United States)

Author keywords

Asia; Clinical trial; Smoking; Smoking cessation; Varenicline

Indexed keywords

AMFEBUTAMONE; CARBON MONOXIDE; NICOTINE; NICOTINE GUM; NOSE SPRAY; PLACEBO; VARENICLINE;

ABNORMAL DREAMING; AGGRESSION; AGITATION; ANGINA PECTORIS; ANXIETY DISORDER; ARTICLE; ASIAN; CHINA; CLINICAL TRIAL; CONSTIPATION; COUNSELING; DEPRESSION; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FOLLOW UP; HUMAN; INHALER; INSOMNIA; JAPAN; KOREA; LOZENGE; NAUSEA; NEUROLOGIC DISEASE; NICOTINE REPLACEMENT THERAPY; POPULATION RESEARCH; RACE DIFFERENCE; SIDE EFFECT; SINGAPORE; SKIN DISEASE; SLEEP DISORDER; SMOKING CESSATION; TAIWAN; THAILAND; THERAPY EFFECT; TOBACCO DEPENDENCE; TRANSDERMAL PATCH; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; UPPER ABDOMINAL PAIN;

ADULT; AGED; ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; BENZAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NICOTINIC AGONISTS; PLACEBOS; POPULATION; QUINOXALINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 77955634428     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.505130     Document Type: Article

References (23)

1. Mackay J, Eriksen M, Shafey O. The Tobacco Atlas, 2nd edn. 2006. Atlanta, GA: American Cancer Society
2. Gu D, Kelly TN, Wu X, et al. Mortality attributable to smoking in China. N Engl J Med 2009;360:150-159
3. Katanoda K, Marugame T, Saika K, et al. Population attributable fraction of mortality associated with tobacco smoking in Japan: a pooled analysis of three large-scale cohort studies. J Epidemiol 2008;18:251-264
4. Wen CP, Tsai SP, Chen CJ, et al. Smoking attributable mortality for Taiwan and its projection to 2020 under different smoking scenarios. Tob Control 2005;14(Suppl 1):i76-80
5. Jee SH, Yun JE, Park JY, et al. Smoking and cause of death in Korea: 11 years follow-up prospective study. Korean J Epidemiol 2005;27:182-190
6. Woodward M, Lam TH, Barzi F, et al. Smoking, quitting, and the risk of cardiovascular disease among women and men in the Asia-Pacific region. Int J Epidemiol 2005;34:1036-1045
7. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296:47-55
8. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustainedrelease bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296:56-63
9. Tonstad S, Tønnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006; 296:64-71
10. Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo-and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006;166:1561-1568
11. Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006;166:1571-1577
12. Nakamura M, Oshima A, Fujimoto Y, et al. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007;29:1040-1056
13. Tsai ST, Cho HJ, Cheng HS, et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 2007;29:1027-1039
14. Wang C, Xiao D, Chan KP, et al. Varenicline for smoking cessation: a placebocontrolled, randomized study. Respirology 2009;14:384-392
15. Nides M, Glover ED, Reus VI, et al. Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Am J Health Behav 2008; 32:664-675
16. Fagerström K, Furberg H. A comparison of the Fagerström Test for Nicotine Dependence and smoking prevalence across countries. Addiction 2008;103: 841-845
17. Perkins KA. Smoking cessation in women. Special considerations. CNS Drugs 2001;15:391-411
18. Mwenifumbo JC, Tyndale RF. Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. Pharmacogenomics 2007;8:1385-1402
19. Benowitz NL, Swan GE, Jacob 3rd P, et al. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin Pharmacol Ther 2006;80: 457-467
20. Curry S, Marlatt GA, Gordon JR. Abstinence violation effect: validation of an attributional construct with smoking cessation. J Consult Clin Psychol 1987;55:145-149
21. Tonstad S, Davies S, Flammer M, et al. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug Saf 2010;33:289-301
22. Gunnell D, Irvine D, Wise L, et al. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009;339:b3805
23. Purvis TL, Nelson LA, Mambourg SE. Varenicline use in patients with mental illness: an update of the evidence. Expert Opin Drug Saf 2010; 9:471-482